Immunodominant PstS1 antigen of is a potent biological response modifier for the treatment of bladder cancer-2

<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biological response modifier for the treatment of bladder cancer"</p><p>BMC Cancer 2004;4():86-86.</p><p>Published online 26 Nov 2004</p><p>PMCID:PMC544192.</p><p>Copyright © 2004 Sänger et al; licensee BioMed Central Ltd.</p> = 0.01) or PstS1 (10 μg / ml) for three days and afterwards analyzed by flow cytometry for the expression of CD1a, CD14, CD83 and CD86. Isotype control = filled histograms, specific antibody = open histograms. Cells were gated on intact dendritic cells according to forward scatter and sideward scatter. Supernatants of the stimulated DCs were collected and ELISAs for TNF-α and IL-12p70 were performed. One representative experiment out of 5 is shown (mean ± SD). n.d. = not detectable